Meticulous Research®—a leading global market research company, published a research report titled 'Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User - Global Forecast to 2031.’

According to this latest publication from Meticulous Research®, the monoclonal antibodies market is projected to reach $449.8 billion by 2031, at a CAGR of 11.2% from 2024 to 2031. The growth of this market is driven by the high burden of cancer and autoimmune diseases globally, increasing funding for clinical trials and research, growth in the biopharmaceutical industry, rising prevalence of infectious diseases, and increasing research in proteomics and genomics. However, the availability of alternative diagnostic tests and the high costs & time required for antibody development restrain the market’s growth.

Furthermore, increasing R&D investments by pharmaceutical & biotech companies, expanding applications of antibodies in clinical trials and medical research, increasing research activities in developing countries, the rising need for new biomarker identification, and initiatives aimed at enhancing diagnostic testing are expected to create market growth opportunities. However, the inaccuracy of antibody tests, high manufacturing costs, concerns regarding the quality & stability of research antibodies, and complexities in the production process are some of the challenges impeding the market’s growth.

Download Free Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5929

Key Players
The key players operating in the monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

Monoclonal Antibodies Market: Future Outlook
The monoclonal antibodies market is segmented by Type (Research Monoclonal Antibodies [Research Area {Oncology, Infectious Diseases, Cardiology, Immunology, Neurology, Stem Cell Research, and Other Research Areas}, Application {Proteomics, Drug Discovery and Development, and Genomics}, and Technology {Flow Cytometry, Immunofluorescence, Enzyme-Linked Immunosorbent Assay, Multiplex Immunosorbent Assay, Western Blot, Immunohistochemistry, Immunoprecipitation (IP), Other Research Technologies}], Diagnostic Monoclonal Antibodies [Application {Oncology, Infectious Diseases , Pregnancy Detection/Fertility Testing, Cardiac Marker Testing, and Other Diagnostic Applications} and Technology {ELISA, Lateral Flow Assay, Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blot (WB), Immunocytochemistry (ICC), and Other Diagnostic Technologies}], and Therapeutic Monoclonal Antibodies [Therapeutic Area {Oncology, Autoimmune Diseases, Neurological Diseases, Infectious Diseases, Other Therapeutic Areas} and Route of Administration {Subcutaneous and Intravenous}]), Production Process (In Vivo Process and In Vitro Process [Upstream Process and Downstream Process]), Source (Human, Humanized, Murine, Chimeric, Other Sources), End User (Pharmaceutical & Biotechnology Companies, Hospitals, Contract Research Organizations, and Other End Users), and Geography. The study also evaluates industry competitors and analyzes the market at the global and regional levels.

Among the types covered in this report, in 2024, the therapeutic monoclonal antibodies segment is expected to account for the largest share of 90.2% of the monoclonal antibodies market. This segment’s large market share can be attributed to advancements in discovery and development technologies and increased demand for biosimilars following the expiration of drug patents. Moreover, the increasing demand for targeted cancer therapy, coupled with supportive initiatives for antibody development and approval processes, contributes to the significant market share of this segment.

Among the production processes covered in this report, in 2024, the in vitro process segment is expected to account for the largest share of the monoclonal antibodies market. This segment’s large market share can be attributed to advancements in recombinant technology and the benefits offered by in vitro production processes, such as minimized batch-to-batch variability, scalability, and cost-effectiveness. Moreover, the utilization of in vitro production processes enables the creation of monoclonal antibodies without the need for extensive animal testing, thereby mitigating ethical concerns associated with animal experimentation.

Among the sources covered in this report, in 2024, the human segment is expected to account for the largest share of 33.2% of the monoclonal antibodies market. This segment's large market share can be attributed to the advancements in cell culture & biotechnology techniques and the increasing number of drug launches and product approvals for human monoclonal antibodies, which demonstrate high specificity and often do not induce a significant immune response or trigger immune reactions in the body. Additionally, they offer a reduced risk of cross-reactivity and ease of cost-effective large-scale production.

Among the end users covered in this report, in 2024, the hospitals segment is expected to account for the largest share of the monoclonal antibodies market. This segment’s large market share can be attributed to the proliferation of public and private hospitals, the increasing prevalence of chronic diseases leading to higher hospital admissions, the rising number of healthcare facilities in emerging economies, and the growing availability of monoclonal antibody therapies in healthcare settings. Additionally, the availability of reimbursement policies for monoclonal antibody treatment at hospitals contributes to the growth of this segment.

Quick Buy – Monoclonal Antibodies Market - Global Opportunity Analysis and Industry Forecast (2024-2031), Research Report: https://www.meticulousresearch.com/Checkout/78623691

Geographic Review
This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa.

Among the regions covered in this report, the market in Asia-Pacific is projected to register the highest CAGR of 13.4% during the forecast period. The growth of this regional market is driven by factors such as the rising incidence of diseases, increasing research activities, availability of cost-effective biosimilar options, large population, rising healthcare expenditures, technological advancements, and supportive government initiatives for clinical trials.

Scope of the Report:
Monoclonal Antibodies Market Assessment, By Type
• Research Monoclonal Antibodies
o Research Area
 Oncology
 Infectious Diseases
 Cardiology
 Immunology
 Neurology
 Stem Cell Research
 Other Research Areas
o Application
 Proteomics
 Drug Discovery and Development
 Genomics
o Technology
 Flow Cytometry
 Immunofluorescence
 Enzyme-Linked Immunosorbent Assay
 Multiplex Immunosorbent Assay
 Western Blot
 Immunohistochemistry
 Immunoprecipitation (IP)
 Other Research Technologies
• Diagnostic Monoclonal Antibodies
o Application
 Oncology
 Infectious Diseases
 Pregnancy Detection/Fertility Testing
 Cardiac Marker Testing
 Other Diagnostic Applications
o Technology
 ELISA
 Lateral Flow Assay
 Immunohistochemistry (IHC)
 Immunoprecipitation (IP)
 Western Blot (WB)
 Immunocytochemistry (ICC)
 Other Diagnostic Technologies
• Therapeutic Monoclonal Antibodies
o Therapeutic Area
 Oncology
 Autoimmune Diseases
 Neurological Diseases
 Infectious Diseases
 Other Therapeutic Areas
o Route of Administration
 Subcutaneous
 Intravenous Cell Therapy
(Note 1: Other research areas include Ophthalmology and Rare Diseases)
(Note 2: Other research technologies include electrophoretic mobility shift assay (EMSA) and enzyme-linked immunospot (ELISPOT) assay)
(Note 3: Other diagnostic applications include Alzheimer’s, autoimmune diseases, cardiac diseases, and diabetes.)
(Note 4: Other diagnostic technologies include Immunofluorescence, flow cytometry, in situ hybridization, dot blot, and radioimmunoassay.)
(Note 5: Other therapeutic areas include cardiac diseases, diabetes, ophthalmology, and hematology.)

Monoclonal Antibodies Market Assessment, By Production Process
• In Vivo Process
• In Vitro Process
o Upstream Process
o Downstream Process

Monoclonal Antibodies Market Assessment, By Source
• Human
• Humanized
• Chimeric
• Murine
• Other Sources
(Note: Other sources include goat, sheep, chicken, and llama)

Monoclonal Antibodies Market Assessment, By End User
• Pharmaceutical & Biotechnology Companies
• Hospitals
• Contract Research Organizations
• Other End Users
(Note: Other end users include Academic & research institutes, nursing centers, and long-term care centers)

Monoclonal Antibodies Market Assessment, by Geography
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o Italy
o U.K.
o Spain
o Switzerland
o Belgium
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o South Korea
o Australia
o Rest of Asia-Pacific
• Latin America
o Brazil
o Mexico
o Rest of Latin America
• Middle East & Africa

Request Free Research Report Sample @ https://www.meticulousresearch.com/request-sample-report/cp_id=5929

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- [email protected]
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research